

1 **Review title**

2 Social determinants of adult health outcomes in Sickle cell disease: a scoping review protocol

3 **Alphanso Blake<sup>1</sup>, Nadia Bennett<sup>1</sup>, Trevor Ferguson<sup>1</sup>, Seeromanie Harding<sup>2</sup>, Monika Asnani<sup>3</sup>.**

4 1. Epidemiology Research Unit, Caribbean Institute for Health Research, The University of the West  
5 Indies, Mona, Jamaica.

6 2. School of Life Course Sciences, Faculty of Life Sciences & Medicine, King's College London,  
7 London, UK.

8 3. Sickle Cell Unit, Caribbean Institute for Health Research, University of the West Indies, Mona,  
9 Jamaica.

10

11 **Abstract**

12 **Objective:** To summarize the evidence and identify gaps in the literature related to the impact of social  
13 factors on health outcomes across the life course for persons with Sickle Cell Disease.

14 **Introduction:** Sickle cell disease (SCD) is a group of genetic diseases where abnormal hemoglobin is  
15 associated with recurrent complications across the life course which results in increased morbidity or  
16 death. The social determinants of health may impact health outcomes throughout the life course of  
17 these individuals. Better understanding of the effect that these factors and their complications have may  
18 influence management approaches both medically and socially to improve quality of life.

19 **Inclusion criteria:** All studies published in English between 1973 and 2023 of persons of all ages living  
20 with SCD (SS, SC, SB<sup>0</sup> SB<sup>+</sup>), examining factors related to the social determinants of health will be  
21 included. Conference abstracts, editorials and opinion papers will be excluded.

22 **Methods:** Methods proposed by the Joanna Briggs Institute (JBI) and by Westphaln and colleagues in  
23 2021 will be used. The electronic databases Academic Search Ultimate (EBSCO), Open Science  
24 Framework and PubMed will be searched using a pre-specified search strategy developed with

25 stakeholder input. All citations will be reviewed by two independent reviewers with disagreements  
26 adjudicated by a third reviewer. The screening process will be reported in a Preferred Reporting Items  
27 for Systematic Reviews Extensions for Scoping reviews (PRISMA- ScR) flow diagram. The Rayyan  
28 software will be used to manage the review process.

29 **Keywords:** Life course, social determinants, sickle cell disease, morbidity, scoping review protocol

## 30 **Introduction**

31 Sickle cell disease (SCD) is one of the most common hereditary disorders globally, predominantly  
32 affecting populations of African and Indian descent (1, 2). Although the pathophysiological effects of the  
33 condition has been extensively studied, the non-genetic factors such as socioeconomic and climate  
34 factors has not been as widely reviewed, especially in low income settings (3). The USA has less than 1%  
35 of persons with SCD, in Populations in Africa the prevalence varies between 2 and 30% and, and in  
36 Jamaica 10% of the population carries the HbS gene (3-5). The four commonest types of SCD in Jamaica  
37 are homozygous SS, SC, SB<sup>0</sup> thalassemia, and SB<sup>+</sup> thalassemia. The disease is characterized by multiple  
38 acute and chronic sequele (6) which can have deleterious effects on an individuals' development in  
39 childhood and social and economic positions in adulthood. These effects are a result of missed school  
40 days which are associated with lower academic ability and poorer job prospects. (6, 7).

41

### 42 *Social Determinants of Health*

43 Factors such as access to healthcare, parental occupation, community socioeconomic status and  
44 educational attainment continue to play a significant role in the quality-of-life, and impact health  
45 outcomes. These factors can be grouped under a major heading called Social Determinants of Health  
46 (SDoH)(8). Social determinants of health have been defined as the conditions in which people are born,  
47 grow, work, live, age, and the wider set of forces and systems shaping the conditions of their daily life  
48 (9). There is a myriad of factors, of which the World Health Organization (WHO) has outlined ten,  
49 namely social gradient, stress, early life, social exclusion, work, unemployment, social support,  
50 addiction, food and transport as a lens through which social determinants of health can be classified or  
51 viewed (8). The above-mentioned factors can be used to assess an individual's situation as they progress  
52 throughout their course of life. Adopting a life course approach to the review of the conditions people

53 are exposed to rather than a snapshot approach can offer a more thorough and complete understanding  
54 of challenges faced at all ages and how the factors interact with each other(10).

55 The Sustainable Development Goals look at good health and wellbeing (Goal 3) and Reducing  
56 inequalities (Goal 10), the SDoH construct is a central ingredient to all action (10, 11). The SDoH  
57 construct does well to incorporate the work of George Engel 1977 which involves the conceptualization  
58 of the biopsychosocial model to care (12). Engels posits that in order to understand a person's medical  
59 condition adequately, one needs to factor in their psychological and social situation which forms an  
60 interplay with their biological situation(12). Authors in recent times built on Engel's work and emphasize  
61 that approaches to handling social inequities in health should consider the determinants which often lies  
62 outside the health system such as poverty, income, employment status and education. (10).

63

#### 64 Morbidity in SCD

65 Morbidity factors include acute and chronic severe bone pain may affect the extremities, chest and back  
66 (2). Acute pain is especially common in adolescents and young adults and is seen more frequently in  
67 persons with the homozygous HbSS genotype. Severe pain episodes are often managed at home  
68 without the involvement of health providers. Persons with the condition have at least 0.8 ( $\approx 1$ )  
69 significant episode of pain per year, with over 5% having 3 - 10 episodes yearly (1).

70 Acute chest syndrome is the second most common complication in SCD and is characterized by chest  
71 pain, fever, dyspnea, and decreased oxygen saturation (13). It is a form of acute lung injury which can  
72 occur after an acute pain event and carries a risk for respiratory and multiorgan failure(13). Researchers  
73 have found that it can result in significant mortality, of up to 9 or 10% of cases in adults with SCD (2, 13,

74 14). The condition is associated with an average hospitalization of 10.5 days and decreased long-term  
75 survival and as such is considered a medical emergency treatable in hospital immediately (13).

76 Acute stroke is a serious and potentially debilitating complication in SCD; this includes ischaemic and  
77 haemorrhagic events and presents as a medical emergency(2). Ischaemic stroke is caused by an  
78 occlusion of a cerebral artery resulting from deoxygenated red blood cells which deform into a rigid  
79 sickle shape, it can also be a result of complications of other SCD-related events(2). Ischaemic stroke  
80 may be preceded by, transient ischaemic attacks, which are characterized by sudden onset of focal  
81 weakness or alteration in mental state, lasting less than twenty-four hours while ischaemic strokes last  
82 longer than 24 hours (2). Children with SCD have a 3 times greater risk of acute stroke than other  
83 children and by the age of 45 years, 25% of individuals with SCD would have had a stroke (2).

84 Sickle cell leg ulcers are a common complication and their prevalence is affected by the individual's age,  
85 genotype, and geographical location (15). It is the most common cutaneous presentation of SCD and  
86 occurs as early as the teenage years (16, 17). The condition is most common in persons with HbSS and  
87 persons with West African origins, wherein Jamaica has a very high (70% - 80%) prevalence, while other  
88 areas report a lower prevalence (18). Additionally, a study from the USA has reported leg ulceration to  
89 be more common in males than in females(15). The variety of ulcers that have been found can be  
90 categorized into three groups, namely, single ulcers, recurrent ulcers and chronic recurrent ulcers (19).  
91 Chronic leg ulceration can result in intense, chronic and unrelenting pain which is difficult to manage  
92 (16). Leg ulcerations negatively impact one's quality of life, resulting in depression in some cases (16).  
93 Regardless of the many complications of SCD, more patients with the condition are living longer due to  
94 the introduction of newborn screening, simple early childhood interventions, better health maintenance  
95 and the introduction of novel therapies (20). The median age of death, however, remains lower than the

96 general population wherein individuals with SCD live up to 22 fewer years (54 vs 76 years) and have a  
97 quality-adjusted life expectancy of half that of individuals without SCD (33 vs 67 years) (7, 21). The  
98 median age of death in the Jamaican cohort is 42.3 years(22).

99 The life course approach to chronic diseases theorizes that the accumulation and or interaction of  
100 socio-economic, biological and psychosocial experiences throughout the life course of an individual will  
101 ultimately impact adult health outcomes, a number of models have been put forward to explain life  
102 course (23).

103 A preliminary search of the PubMed database was conducted as a pilot exercise. One Scoping review  
104 study was found which looked at the relationship between sickle cell disease and social determinants of  
105 health by Khan 2022 (24). The results of this scoping review study had fifty-nine articles which were  
106 classified under 5 SDoH headings, namely, Neighbourhood and built Environment (11 studies), Health  
107 and Health Care (15 studies), Social and Community Context (18 studies), Education (5 studies) and  
108 Economic Stability (11 studies). This list may not fit under all the WHO classification listed above except  
109 for economic stability (work) and social and community context (social support). Most of the studies  
110 described by Khan were from the United States (43 studies) and the United Kingdom (6 studies). Gaps  
111 detailed by the study include that most research was limited to children and caregivers, and none were  
112 found that assessed the longitudinal impact of social determinants of health (24). No grey literature was  
113 searched in Khan's work, exclusion of grey literature may be considered a limitation as smaller studies  
114 presented at conferences, as part of academic work or that have not reached publication status would  
115 have been missed. No other systematic reviews or scoping reviews were found in the search.

116

117 This scoping review will aim to identify and map the social determinants that have shown associations

118 with health outcomes including pain events, hospitalizations, acute chest syndrome, stroke, and quality  
119 of life across the life course of individuals with sickle cell disease. This study will also aim to ascertain the  
120 longitudinal association of SDoH factors and health outcomes in SCD to address the gaps found in the  
121 study by Khan (24). Finally, these findings will assist in filling knowledge gaps related to the area and  
122 provide a basis for future research and development.

123

#### 124 **Review question(s)**

125 What are the social determinants that have been shown to be associated with health outcomes across  
126 the life course of persons with Sickle Cell Disease?

- 127 I. What measures have been used for measuring SDoH in published studies on Sickle cell disease?  
128 II. What is the existing evidence of the association between Social Determinants of Health (SDOH)  
129 and Sickle Cell Disease (SCD) over the life course?  
130 III. How many studies have examined the intersectionality between Social Determinants of Health  
131 (SDOH) and Sickle Cell Disease (SCD)?

#### 132 **Inclusion criteria**

##### 133 **Participants**

134 This review will consider studies that have been reported on persons with SCD (HbSS, HbSC, Hb S $\beta$ 0 thal,  
135 Hb S $\beta$ + thal). All study designs will be included.

##### 136 **Concept**

137 This review will consider studies that explore predictors such as socioeconomic status, parental  
138 occupation, environmental factors, and health service accessibility. Secondly, outcomes will be assessed

139 in manuscripts which included quality of life, hospitalization, complications (leg ulcers, acute chest  
140 syndrome, strokes, painful crises, kidney disease) and death.

#### 141 **Context**

142 This review will consider studies that were published between 1973 and 2023 (inclusive), from all world  
143 regions. Studies not published in English and opinion papers will be excluded.

#### 144 **Types of sources**

145 This scoping review will consider qualitative, quantitative, and mixed methods study designs for  
146 inclusion. Studies done using a qualitative methodology are expected to offer rich, thick data. Finally,  
147 systematic, and scoping reviews that match the inclusion criteria will be considered, and their reference  
148 list combed to identify additional studies that are relevant to the research question. Text, conference  
149 abstracts and opinion papers will not be considered, and neither will studies which are not written in  
150 English.

#### 151 **Methods**

152 The scoping review will be conducted following the JBI methodology for scoping reviews documented by  
153 Peters and colleagues in 2015 and supported by recommendations from Westphaln and colleagues in  
154 2021 (20, 21). It will also be conducted in line with the Preferred Reporting Items for Systematic Reviews  
155 and Meta-Analyses extensions for Scoping Reviews (PRISMA-ScR (25-27)).

#### 156 **The Review team**

157 The study team will consist of three reviewers, AB the primary researcher, NB who has experience in  
158 systematic review methodologies and MA who is on the team as a senior researcher and content expert.



159 Consultations will be sought from relevant stakeholders inclusive of specialist SCD physicians, social  
160 worker, nurse, patients with SCD and their proxies. This is detailed in the consultation section below.

### 161 **Search strategy**

162 The search strategy will identify published and unpublished studies. Using an iterative process Academic  
163 Search Ultimate (EBSCO), Open Science Framework and PubMed databases will be searched. The  
164 PubMed database was searched on June 9<sup>th</sup>, 2023, as part of a piloting exercise. The search terms are  
165 detailed in appendix 1.

166 The reference list of systematic reviews identified as well as studies identified for inclusion will be  
167 screened for any potentially relevant articles which may have been missed by the search strategy. Grey  
168 literature sources will include American Society of Hematology, Sickle Cell in Focus and Global Congress  
169 on Sickle Cell Disease conference documents which were identified by AB and MA the content expert.  
170 All citations retrieved will be stored in Endnote 20 and uploaded into Rayyan. All duplicates will be  
171 removed.

### 172 **Study/Source of evidence selection**

173 Following the search, all identified records will be collated and uploaded into EndNote 20 and duplicate  
174 removed. Following a pilot test, titles and abstracts will then be screened by two independent reviewers  
175 for assessment against the inclusion criteria for the review. Potentially relevant papers will be retrieved  
176 in full, and their citation details imported into the Raayan software for full assessment and review. The  
177 full text of selected citations will be assessed in detail against the inclusion criteria independently by AB  
178 and NB. Any disagreements on suitability for inclusion in the study will be arbitrated by MA who will  
179 have the final decision. Reasons for the exclusion of full-text papers that do not meet the inclusion

180 criteria will be recorded and reported in the scoping review. The results of the search will be reported in  
181 full in the final scoping review and presented in a PRISMA flow diagram(25).

182

## 183 **Data extraction**

184 Data will be extracted from papers included in the scoping review by AB and NB using a data extraction  
185 tool developed by NB. The data extraction form will capture the author's name, study year, study  
186 location, community of residence, hospitalization, social amenities scores, educational status, parental  
187 educational status, and occupation as SDoH proxies as well as outcome variables (Stroke, acute chest,  
188 pain events, hospitalization, and mortality). Additionally, the population of the study, sample size, aims,  
189 methodology, study design used, key results and limitations will be extracted. Data abstraction will be  
190 conducted by AB and NB independently and consolidated to ensure the completeness of the  
191 information retrieved. MA will make the final decision on any questions raised or disagreements  
192 between AB and NB. Authors of papers will be contacted to request missing or additional data, where  
193 required. The data will thereafter be summarized and coded in a simple qualitative format in excel. A  
194 draft of the extraction form is available in Appendix II. In keeping with the iterative nature of a scoping  
195 review, the extraction form will be amended if necessary. All modifications made to the data extraction  
196 form will be detailed in the final report.

## 197 **Data analysis and presentation**

198 The consultation team along with the review team will come together to examine the findings to ensure  
199 that they are relevant and in keeping with the proposed objectives/intentions of the study. Qualitative  
200 data will be sorted by two members of the research team. Results will be coded as themes and classified  
201 into morbidity factors and social determinants of health factors associated with each morbidity factor.

202 Quantitative data such as the number of participants in each study, age, and age of onset of morbidity  
203 factor will be summarized as means and standard deviation or median and interquartile range as  
204 appropriate. Following the feedback from all members of the consultation team, data will be  
205 summarized and represented in a tabular form to all members for consolidation of findings. Finally, a  
206 narrative summary will accompany each table, thus describing how the findings connect to the intended  
207 aim of the review.

208

## 209 **Consultation**

210 Westphaln 2021 considers consultation an integral part of a scoping review and not just an optional  
211 feature (28). The consultation exercise is expected to add legitimacy to the findings and the  
212 trustworthiness of the consultants is expected to be transparent and rigorous(29). This Sickle Cell Unit  
213 (SCU) is the specialised comprehensive care facility for persons with SCD in Jamaica and hence provides  
214 a useful proxy for the experiences of persons on the island. A consultation team including members of  
215 staff from the SCU and SCD patient support group will be assembled. The team members will be a social  
216 worker who works closely with the population of persons with SCD, 2 specialist SCD doctors and a  
217 specialist SCD nurse who has over 10 years of experience with the population. Additionally, two  
218 patients, two parent/guardians of patients (not linked), and two members from SCD peer support  
219 groups will be included on the consultation team. These individuals will be recruited using a purposive  
220 sampling approach. The sessions will be recorded and transcribed for use during the period of the study  
221 and disposed of at the end. Consultation is key as it provides valuable feedback in which knowledge can  
222 be integrated which may not necessarily be accessible via academic literature (28). These may include  
223 cultural practices, historical context and newly developed approaches which may not have been

224 published yet (28). The consultation team will provide input at the beginning and at the end of the  
225 review to ensure that appropriate terms are being used and that the research question stays true to the  
226 intended objective.

## 227 **Dissemination and ethics**

228 Ethical approval was obtained from the Mona Research Ethics Committee (MREC) at the University of  
229 the West Indies (# CREC-MN.0154, 2022/2023).

## 230 **Acknowledgements**

231 Mrs. Faith McKoy-Johnson, a librarian, provided support with the development of the search strategy.

## 232 **Funding**

233 No funding was obtained for this manuscript's development.

## 234 **Declarations**

235 No special declarations are to be made.

## 236 **Author contributions**

237 AB designed the protocol and wrote the manuscript. NB, TF, SH, and MA contributed to the protocol  
238 design and guided the writing of the manuscript. MA and TF contributed to content development and  
239 NB focused on design principles for a review of this nature. All authors agree with the final version of the  
240 manuscript for submission.

241

## 242 **Conflicts of interest**

243 The authors declare no conflict of interest.

## 244 References

- 245 1. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. *Lancet*. 2010;376(9757):2018-31.
- 246 2. Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, et al. Sickle cell  
247 disease. *Nat Rev Dis Primers*. 2018;4:18010.
- 248 3. Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. *N Engl J Med*. 2017;376(16):1561-73.
- 249 4. Bhatt K, Reid ME, Lewis NA, Asnani MR. Knowledge and health beliefs of Jamaican adolescents  
250 with sickle cell disease. *Pediatric Blood & Cancer*. 2011;57(6):1044-8.
- 251 5. Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. *Lancet*.  
252 2017;390(10091):311-23.
- 253 6. Poku BA, Caress A-L, Kirk S. Adolescents' experiences of living with sickle cell disease: An  
254 integrative narrative review of the literature. *International Journal of Nursing Studies*. 2018;80:20-8.
- 255 7. Lubeck D, Agodoa I, Bhakta N, Danese M, Pappu K, Howard R, et al. Estimated Life Expectancy  
256 and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease. *JAMA*  
257 *Netw Open*. 2019;2(11):e1915374.
- 258 8. Wilkinson R, Marmot M, World Health Organization. Regional Office for E. Social determinants  
259 of health: the solid facts. 2nd (en) ed. Copenhagen: World Health Organization. Regional Office for  
260 Europe; 2003 2003.
- 261 9. Addressing Social Determinants to Improve Patient Care and Promote Health Equity: An  
262 American College of Physicians Position Paper. *Annals of Internal Medicine*. 2018;168(8):577-8.
- 263 10. Berghs M, Ola B, Cronin De Chavez A, Ebenso B. Time to apply a social determinants of health  
264 lens to addressing sickle cell disorders in sub-Saharan Africa. *BMJ Global Health*. 2020;5(7):e002601.
- 265 11. Morton S, Pencheon D, Squires N. Sustainable Development Goals (SDGs), and their  
266 implementation: A national global framework for health, development and equity needs a systems  
267 approach at every level. *British medical bulletin*. 2017;124:1-10.
- 268 12. contributors P. Biopsychosocial Model: Physiopedia; [updated 7 November 2022 23:13 UTC].  
269 Available from: [https://www.physio-pedia.com/index.php?title=Biopsychosocial\\_Model&oldid=319922](https://www.physio-pedia.com/index.php?title=Biopsychosocial_Model&oldid=319922).
- 270 13. Novelli EM, Gladwin MT. Crises in Sickle Cell Disease. *Chest*. 2016;149(4):1082-93.
- 271 14. Alishlash AS, Rutland SB, Friedman AJ, Hampton JI, Nourani A, Lebensburger J, et al. Acute chest  
272 syndrome in pediatric sickle cell disease: Associations with racial composition and neighborhood  
273 deprivation. *Pediatr Blood Cancer*. 2021;68(4):e28877.
- 274 15. Serjeant GR, Serjeant BE. Sickle Cell Disease. Third ed. The United States: Oxford University  
275 Press; 1985 2001. 772 p.
- 276 16. Granja PD, Quintão SBM, Perondi F, de Lima RBF, Martins CLM, Marques MA, et al. Leg ulcers in  
277 sickle cell disease patients. *J Vasc Bras*. 2020;19:e20200054.
- 278 17. Altman IA, Kleinfelder RE, Quigley JG, Ennis WJ, Minniti CP. A treatment algorithm to identify  
279 therapeutic approaches for leg ulcers in patients with sickle cell disease. *Int Wound J*.  
280 2016;13(6):1315-24.
- 281 18. Serjeant GR, Serjeant BE, Mohan JS, Clare A. Leg ulceration in sickle cell disease: medieval  
282 medicine in a modern world. *Hematol Oncol Clin North Am*. 2005;19(5):943-56, viii-ix.
- 283 19. Minniti CP, Kato GJ. Critical Reviews: How we treat sickle cell patients with leg ulcers. *Am J*  
284 *Hematol*. 2016;91(1):22-30.
- 285 20. Cintron-Garcia J, Ajebo G, Kota V, Guddati AK. Mortality trends in sickle cell patients. *Am J Blood*  
286 *Res*. 2020;10(5):190-7.
- 287 21. Onimoe G, Rotz S. Sickle cell disease: A primary care update. *Cleveland Clinic Journal of*  
288 *Medicine*. 2020;87(1):19.

- 289 22. Serjeant GR, Chin N, Asnani MR, Serjeant BE, Mason KP, Hambleton IR, et al. Causes of death  
290 and early life determinants of survival in homozygous sickle cell disease: The Jamaican cohort study from  
291 birth. *PLoS One*. 2018;13(3):e0192710.
- 292 23. Pollitt RA, Rose KM, Kaufman JS. Evaluating the evidence for models of life course  
293 socioeconomic factors and cardiovascular outcomes: a systematic review. *BMC Public Health*.  
294 2005;5(1):7.
- 295 24. Khan H, Krull M, Hankins J, Wang W, Porter J. Sickle Cell Disease and Social Determinants of  
296 Health -- A Scoping Review. *Authorea Preprints*; 2022.
- 297 25. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020  
298 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71.
- 299 26. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting  
300 items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev*.  
301 2015;4(1):1.
- 302 27. Peters M, Godfrey C, Mclnerney P, Munn Z, Trico A, Khalil H. Chapter 11: Scoping Reviews. 2020.
- 303 28. Westphaln KK, Regoeczi W, Masotya M, Vazquez-Westphaln B, Lounsbury K, McDavid L, et al.  
304 From Arksey and O'Malley and Beyond: Customizations to enhance a team-based, mixed approach to  
305 scoping review methodology. *MethodsX*. 2021;8:101375.
- 306 29. Buus N, Nygaard L, Berring LL, Hybholt L, Kamionka SL, Rossen CB, et al. Arksey and O'Malley's  
307 consultation exercise in scoping reviews: A critical review. *J Adv Nurs*. 2022;78(8):2304-12.

308

309 **Appendix I: Search strategy**

310 #PubMed June 9<sup>th</sup>, 2023

Search	Query	Records retrieved
#1	(("Anemia, Sickle Cell"[Mesh] OR "Anemias, Sickle Cell" [TW] OR "Sickle Cell Anemias" [TW] OR "Hemoglobin S Disease" [TW] OR "Disease, Hemoglobin S" [TW] OR "Hemoglobin S Diseases" [TW] OR "Sickle Cell Anemia" [TW] OR "Sickle Cell Disorders" [TW] OR "Sickle Cell Disorder" [TW] OR "HbS Disease" [TW] OR "Sickle Cell Disease" [TW] OR "Cell Disease, Sickle" [TW] OR "Cell Diseases, Sickle" [TW] OR "Sickle Cell Diseases" [TW])) <b>AND</b> ("Health Services Accessibility"[MeSH] OR "Access to health care" OR "Access to Health Services" OR "Access to Care" OR "Care, Access to" OR "Accessibility of Health Services" OR "Accessibility, Health Services" OR "Availability of Health Services" OR "Health Services Availability" OR "Access To Care, Health" OR "Treatment, Access to" OR "Health Services Geographic Accessibility" OR "Access to Medicines" OR "Access to Medicine" OR "Medicine, Access to" OR "Medicines, Access to" OR "Access to Medications" OR "Access to Medication" OR "Medication, Access to" OR "Medication Access" OR "Access, Medication" OR "Telemedicine" OR "Equitable access" OR "Specialized care" OR "Access to nutrition" OR "Educational Status"[Mesh] OR "Educational Achievement" OR "Status, Educational" OR "Achievement, Educational" OR "Achievements, Educational" OR "Educational Achievements" OR "Educational Status, Maternal" OR "Status, Maternal Educational" OR "Maternal Educational Status" OR "Educational Status, Paternal" OR "Status, Paternal Educational" OR "Paternal Educational Status" OR "Knowledge" OR "Knowledge Base" OR "Higher education" OR "Anticipatory Knowledge" OR "Anticipatory Guidance" OR "Health Literacy" OR "Parental Education" OR "Education of parents" OR "Parental Interest" OR "Caregiver knowledge" OR "Spending power" OR "Affordability of care" OR "Parental protection" OR "parental Income" OR "patient income" OR "Patients adherence" OR "Treatment compliance" OR "Patient follow-up" OR "Continuation of care" OR "Social support" OR "Family support" OR "Financial support" OR "Quality of Life" OR "Health-related quality of life" OR "Socioeconomic factors" [MeSH] OR "Factor, Socioeconomic" OR "Socioeconomic Factor" OR "Factors, Socioeconomic" OR "Standard of Living" OR "Living Standard" OR "Living Standards" OR "Social Inequality" OR "Inequalities, Social" OR "Inequality, Social" OR "Social Inequalities" OR "awareness" OR "interpersonal relationships" OR "social determinants of health" )	2903
	Limited to 1973 – 2023 and English only	

311 **Appendix II: Data extraction instrument**

312

Author	Year	Study location	Intervention type	Population	Aims	Methodology	SDOH Factors (hospitalization, social amenities scores, educational status, parental educational status, community of residence and occupation)	Outcome measures (Stroke, acute chest, pain events, hospitalization, and mortality)	Data analysis method (quantitative/qualitative)	Results	Sample size	Study design	Morbidity type	Gender



<b>Quantitative</b>	<b>Qualitative</b>	

313